anti-EX02 CAR T cells

Phase 1Cell therapy

ZZhang Xiaofeng,MD

anti-EX02 CAR T cells is one of 26 small molecule programs targeting Bile Duct Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bile Duct CancerActive, not recruiting

Bile Duct CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Bile Duct Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Approved

—2

Photofrin

PPinnacle Biologics Inc.

Ixempra

Gemzar

2 5

Abraxane

Bristol-Myers Squibb

Phase 2

1 6

Lynparza

AstraZeneca

Phase 2

1 7

Koselugo

AstraZeneca

Phase 2

1 8

Keytruda

Merck & Co.

Phase 2

1 9

Imfinzi

Taxol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Bile Duct Cancer

NCT06196658

Clinical

Trials by Indication[1]

Bile Duct Cancer1 trial

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Not yet recruiting·ZZhang Xiaofeng,MD·Phase 1·NCT06196658·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for anti-EX02 CAR T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-EX02 CAR T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-EX02 CAR T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhang Xiaofeng,MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: ZZhang Xiaofeng,MD

anti-EX02 CAR T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Bile Duct Cancer1 trial

References

Drug Info

Quick Facts

Related News